Literature DB >> 18833102

[Comparative efficacy of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].

V V Koval'chuk, A A Skoromets, I V Vasil'eva.   

Abstract

An influence of different muscle relaxants on muscle tone and functional rehabilitation has been studied in 360 post-stroke patients. Muscle tone has been assessed with the Ashworth scale and functional rehabilitation with Barthel, Lindmark and Scandinavian scales as well as the Merton & Sutton scale. Efficacy of muscle relaxants has been assessed by the 2 min. walking test. Moreover, we suggested a coefficient for calculating drug efficacy. The results of the study revealed that tolperisone was the most efficient in the treatment of post-stroke patients with spasticity. Tizanidine was also effective but to a lesser extent. Other drugs studied did not reveal any significant effect. Tolperisone had a good tolerability, the adverse effects in patients treated with this drug were registered more rarely compared to other ones.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18833102

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN: 1997-7298


  3 in total

Review 1.  Pharmacological interventions other than botulinum toxin for spasticity after stroke.

Authors:  Cameron Lindsay; Aphrodite Kouzouna; Christopher Simcox; Anand D Pandyan
Journal:  Cochrane Database Syst Rev       Date:  2016-10-06

2.  Clinical comparative study: efficacy and tolerability of tolperisone and thiocolchicoside in acute low back pain and spinal muscle spasticity.

Authors:  Rajeev Rao; Atul Panghate; Ajay Chandanwale; Indrajeet Sardar; Mriganka Ghosh; Modan Roy; Bireswar Banerjee; Ankur Goswami; Prakash P Kotwal
Journal:  Asian Spine J       Date:  2012-05-31

3.  The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury.

Authors:  Dejun Luo; Guoyong Wu; Yong Ji; Zhaoyao Zhang; Fayou He; Xiaping Mou; Qingmao Zhu; Bo Yang
Journal:  Saudi Pharm J       Date:  2017-05-07       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.